Published on
Feb 25, 2026
Cashing In on ‘Creative Fundamentals’ To Fund Rare Disease R&D
The rare disease space got a huge boost last month when the FDA’s rare pediatric disease priority review voucher program was reauthorized after more than a year in limbo. While a step in the right direction, rare and orphan drug leaders say more needs to …
Source:
BioSpace
-
Pending
